Cargando…
Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4
PURPOSE: Bone defects and nonunions are major clinical skeletal problems. Growth factors are commonly used to promote bone regeneration; however, the clinical impact is limited because the factors do not last long at a given site. The introduction of tissue engineering aimed to deter the diffusion o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626372/ https://www.ncbi.nlm.nih.gov/pubmed/23630418 http://dx.doi.org/10.2147/IJN.S44124 |
_version_ | 1782266186728210432 |
---|---|
author | Shiozaki, Yasuyuki Kitajima, Takashi Mazaki, Tetsuro Yoshida, Aki Tanaka, Masato Umezawa, Akihiro Nakamura, Mariko Yoshida, Yasuhiro Ito, Yoshihiro Ozaki, Toshifumi Matsukawa, Akihiro |
author_facet | Shiozaki, Yasuyuki Kitajima, Takashi Mazaki, Tetsuro Yoshida, Aki Tanaka, Masato Umezawa, Akihiro Nakamura, Mariko Yoshida, Yasuhiro Ito, Yoshihiro Ozaki, Toshifumi Matsukawa, Akihiro |
author_sort | Shiozaki, Yasuyuki |
collection | PubMed |
description | PURPOSE: Bone defects and nonunions are major clinical skeletal problems. Growth factors are commonly used to promote bone regeneration; however, the clinical impact is limited because the factors do not last long at a given site. The introduction of tissue engineering aimed to deter the diffusion of these factors is a promising therapeutic strategy. The purpose of the present study was to evaluate the in vivo osteogenic capability of an engineered bone morphogenetic protein-4 (BMP4) fusion protein. METHODS: BMP4 was fused with a nanosized carrier, collagen-binding domain (CBD), derived from fibronectin. The stability of the CBD-BMP4 fusion protein was examined in vitro and in vivo. Osteogenic effects of CBD-BMP4 were evaluated by computer tomography after intramedullary injection without a collagen–sponge scaffold. Recombinant BMP-4, CBD, or vehicle were used as controls. Expressions of bone-related genes and growth factors were compared among the groups. Osteogenesis induced by CBD-BMP4, BMP4, and CBD was also assessed in a bone-defect model. RESULTS: In vitro, CBD-BMP4 was retained in a collagen gel for at least 7 days while BMP4 alone was released within 3 hours. In vivo, CBD-BMP4 remained at the given site for at least 2 weeks, both with or without a collagen–sponge scaffold, while BMP4 disappeared from the site within 3 days after injection. CBD-BMP4 induced better bone formation than BMP4 did alone, CBD alone, and vehicle after the intramedullary injection into the mouse femur. Bone-related genes and growth factors were expressed at higher levels in CBD-BMP4-treated mice than in all other groups, including BMP4-treated mice. Finally, CBD-BMP4 potentiated more bone formation than did controls, including BMP4 alone, when applied to cranial bone defects without a collagen scaffold. CONCLUSION: Altogether, nanocarrier-CBD enhanced the retention of BMP4 in the bone, thereby promoting augmented osteogenic responses in the absence of a scaffold. These results suggest that CBD-BMP4 may be clinically useful in facilitating bone formation. |
format | Online Article Text |
id | pubmed-3626372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-36263722013-04-29 Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 Shiozaki, Yasuyuki Kitajima, Takashi Mazaki, Tetsuro Yoshida, Aki Tanaka, Masato Umezawa, Akihiro Nakamura, Mariko Yoshida, Yasuhiro Ito, Yoshihiro Ozaki, Toshifumi Matsukawa, Akihiro Int J Nanomedicine Original Research PURPOSE: Bone defects and nonunions are major clinical skeletal problems. Growth factors are commonly used to promote bone regeneration; however, the clinical impact is limited because the factors do not last long at a given site. The introduction of tissue engineering aimed to deter the diffusion of these factors is a promising therapeutic strategy. The purpose of the present study was to evaluate the in vivo osteogenic capability of an engineered bone morphogenetic protein-4 (BMP4) fusion protein. METHODS: BMP4 was fused with a nanosized carrier, collagen-binding domain (CBD), derived from fibronectin. The stability of the CBD-BMP4 fusion protein was examined in vitro and in vivo. Osteogenic effects of CBD-BMP4 were evaluated by computer tomography after intramedullary injection without a collagen–sponge scaffold. Recombinant BMP-4, CBD, or vehicle were used as controls. Expressions of bone-related genes and growth factors were compared among the groups. Osteogenesis induced by CBD-BMP4, BMP4, and CBD was also assessed in a bone-defect model. RESULTS: In vitro, CBD-BMP4 was retained in a collagen gel for at least 7 days while BMP4 alone was released within 3 hours. In vivo, CBD-BMP4 remained at the given site for at least 2 weeks, both with or without a collagen–sponge scaffold, while BMP4 disappeared from the site within 3 days after injection. CBD-BMP4 induced better bone formation than BMP4 did alone, CBD alone, and vehicle after the intramedullary injection into the mouse femur. Bone-related genes and growth factors were expressed at higher levels in CBD-BMP4-treated mice than in all other groups, including BMP4-treated mice. Finally, CBD-BMP4 potentiated more bone formation than did controls, including BMP4 alone, when applied to cranial bone defects without a collagen scaffold. CONCLUSION: Altogether, nanocarrier-CBD enhanced the retention of BMP4 in the bone, thereby promoting augmented osteogenic responses in the absence of a scaffold. These results suggest that CBD-BMP4 may be clinically useful in facilitating bone formation. Dove Medical Press 2013 2013-04-09 /pmc/articles/PMC3626372/ /pubmed/23630418 http://dx.doi.org/10.2147/IJN.S44124 Text en © 2013 Shiozaki et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Shiozaki, Yasuyuki Kitajima, Takashi Mazaki, Tetsuro Yoshida, Aki Tanaka, Masato Umezawa, Akihiro Nakamura, Mariko Yoshida, Yasuhiro Ito, Yoshihiro Ozaki, Toshifumi Matsukawa, Akihiro Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 |
title | Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 |
title_full | Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 |
title_fullStr | Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 |
title_full_unstemmed | Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 |
title_short | Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 |
title_sort | enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626372/ https://www.ncbi.nlm.nih.gov/pubmed/23630418 http://dx.doi.org/10.2147/IJN.S44124 |
work_keys_str_mv | AT shiozakiyasuyuki enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT kitajimatakashi enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT mazakitetsuro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT yoshidaaki enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT tanakamasato enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT umezawaakihiro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT nakamuramariko enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT yoshidayasuhiro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT itoyoshihiro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT ozakitoshifumi enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 AT matsukawaakihiro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4 |